WEDNESDAY, May 7 (HealthDay News) -- A new class of weight-loss drugs that suppresses appetite by blocking cannabinoid receptors in the brain should be used with caution in children, U.S. scientists report.
In research with mice, they found this class of drugs also suppresses the adaptive rewiring of the brain necessary for neural development in young animals. The findings are in the May 8 issue of Neuron.
One such drug is rimonabant (Acomplia), which was developed by Sanofi-Aventis and is awaiting approval by the U.S. Food and Drug Administration. Other pharmaceutical companies are developing similar drugs.
In this study, researchers concluded that a cannabinoid receptor-blocking drug called AM 251 affected experience-dependent cortical plasticity in the brains of juvenile mice. This plasticity is the experience-prompted adaptive rewiring of the brain that plays an critical role in the neural development of young animals.
"Our finding of a profound disruption of cortical plasticity in juvenile mice treated with AM 251 suggests caution is advised in the use of such compounds in children," wrote Mark F. Bear and his colleagues, of the Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, in Cambridge, Mass.
More information
The Nemours Foundation has more about childhood obesity.
SOURCE: Cell Press, news release, May 7, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Today's Top News Stories |
• | FDA Touts Efforts to Enhance Food Safety - Dec 01, 2008, 17:00
Critics see problems with the agency's goals, commitment and resources. |
• | Clinical Trials Update: Dec. 1, 2008 - Dec 01, 2008, 10:54
- Cervical Cancer
- Migraine and Cluster Headaches
- Hot Flashes
|
• | Few Young Adults Seek Treatment for Psych Disorders - Dec 01, 2008, 17:00
Alcohol, nicotine use, personality illnesses common, study shows. |
• | Antibiotics Largest Cause of Drug-Induced Liver Damage - Dec 01, 2008, 16:00
Prescription meds, supplements can also trigger acute organ failure, study says. |
• | Hopes for AIDS Vaccine Still Alive Despite Setbacks - Dec 01, 2008, 09:00
The lesson from 2 failed trials: The science must be more vigorous, experts say. |
